Trevena Reports Second Quarter 2022 Results and Provides Business Update
August 2022 "CHESTERBROOK, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the...
Trevena Reports Second Quarter 2022 Results and Provides Business Update
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ...
Trevena Announce Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu ...
Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team